Dr. Blanchard joined the Board of Directors in November 2019 following the acquisition of Microchips Biotech. Dr. Blanchard served as President and CEO of Microchips Biotech from 2014 through the company’s acquisition by Daré. Microchips’ innovative drug delivery technology is designed to store and precisely deliver hundreds of therapeutic doses over months or years in a single implant. With the support of the Bill & Melinda Gates Foundation, and under Dr. Blanchard’s leadership, Microchips has been developing an implantable long-acting, reversible contraceptive application of the technology. Dr. Blanchard currently serves as President and CEO of Anika Therapeutics, a biomedical joint preservation company that leverages proprietary regenerative and restoration therapies to help people feel better faster and remain active. She also serves on the board of Neuronetics and on private equity and venture backed company boards as well. Her prior experience includes Senior Vice President, Chief Scientific Officer and General Manager of Biologics at Zimmer, Inc., responsible for Global R&D, Quality, Regulatory and Clinical Affairs, Health Economics and the Regenerative Medicine Business. Dr. Blanchard received her MS and PhD in Materials Science and Engineering from the University of Texas at Austin and her BS in Ceramic Engineering from Alfred University. She is also a member of the National Academy of Engineering.